Summary Primatene Mist inhalers provide temporary relief from mild, intermittent asthma symptoms. They are the only OTC ...
Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in ...